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Abstract 
Rabbit secretin, which differs from all other mammalian secretins in having a Leu residue in position 6 (instead of Phe) 
and a basic residue (Arg) in position 16, had a lower affinity than porcine secretin on recombinant rat secretin receptors but 
had a greater affinity than porcine secretin on recombinant rat VIP~ and PACAP I receptors. Synthetic [L 6 ] porcine secretin 
had a reduced potency on secretin and VIP l receptors whereas [R 16 ] porcine secretin had a similar binding profile as rabbit 
secretin. Thus, an arginine residue in position 16 reduced 3-fold the affinity of secretin for secretin receptors but increased 
30-fold its affinity for the VIP 1 and PACAP I receptors. The introduction of an arginine residue in position 16, instead of 
glutamine, in VIP and PACAP had a similar effect: [R 16 ] VIP and [R 16 ] PACAP had 3- to 10-fold higher affinities than VIP 
and PACAP for VIP~ and PACAP I receptors, and 3-fold lower affinities for the secretin receptors. The three [RI 6 ] peptides 
also had a reduced potency on the chimeric receptor consisting of the N-terminal part of the secretin receptor grafted on the 
VIP l receptor, and an enhanced potency on the chimeric receptor consisting of the N-terminal part of VIP~ receptor grafted 
on the secretin receptor, indicating that position 16 of each ligand interacted with the N-terminal extracellular domain of the 
receptors. 
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1. Introduction 
The study of structure-activity relationships of Va- 
soactive Intestinal Polypeptide (VIP), Pituitary 
Adenylate Cyclase Activating Polypeptide (PACAP) 
and secretin has revealed the existence of different 
Abbreviations: VIP, vasoactive intestinal polypeptide; PACAP, 
pituitary adenylate-cyclase activating polypeptide; secretin, 
porcine secretin 
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domains responsible for high affinity binding, cou- 
pling to the effector system and discrimination be- 
tween receptor subclasses as well as the importance 
of several amino acid side chains. (a) The N-terminal 
sequence is required for a high affinity binding as 
well as for an efficient coupling to the effector; for 
instance, the fragments (2-27) of secretin [1,2], (2-  
28) of VIP [3,4], (2-27) or (2-38) of PACAP [5,6] 
have a low affinity for the receptors and are partial 
agonists; shorter fragments like (5-27) secretin [7,8], 
(10-28) VIP [9], (6-27) and (6-38) PACAP [6,10] 
also have a low affinity for their receptors, and are 
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devoid of biological activity. (b) The C-terminal se- 
quence is also necessary for a high affinity binding 
[11]. However, C-terminally truncated peptides which 
retain the ability to bind to the receptors have a full 
biological activity. (c) The central part (10-21) is 
considered as a spacer domain adopting a c~-helical 
conformation [12,13] and the side chains of the cen- 
tral residues, as not essential for receptor binding. 
Indeed systematic replacement of the amino acids in 
positions 11 to 21 by alanine had limited conse- 
quences [11], and the 13 to 21 VIP sequence could be 
replaced by a phenothiazine ring with a 10-fold re- 
duction only in peptide potency [13]. 
Characterization f natural variants of an hormone 
may help to identify unexpected residues necessary 
for receptor ecognition. Rabbit secretin, which dif- 
fers from the porcine secretin in positions 6 (Leu in 
place of Phe), 16 (Arg in place of Ser) and 27 
(Leu-NH 2 in place of Val-NH 2) [14] (Table 1), had a 
lower affinity than porcine secretin for the rat se- 
cretin receptor, but a higher affinity for the VIP 1 
receptor. We therefore synthesized porcine secretin 
analogues modified in positions 6 and 16, and found 
that the introduction of an arginine residue in position 
16 was responsible for the increased affinity of rabbit 
secretin for the VIPI receptor. 
We reasoned that a similar modification of the VIP 
and PACAP sequences (replacement of Gln 16 by 
Arg) might also increase the peptide affinity for the 
receptors. This was indeed the case. Furthermore, 
taking advantage of the opposite effect of the Arg  16 
replacement on the affinity of secretin, VIP and 
PACAP for the secretin and VIP~ receptors, we found, 
by using chimeric receptors with the N-terminal por- 
tion of each receptor grafted on the core of the other 
receptor, that position 16 of the ligand interacted with 
the N-terminal domain of the receptors. 
2. Materials and methods 
2.1. Cell lines used for receptor characterization 
The DNA coding for the rat secretin receptor 
[2,15], the PACAP type I receptor [5,16], the PACAP 
type II VIP~ receptor [3,17], the chimeric N-Sn/VIP~ 
and N-V IP JSn  receptors [18] were cloned into a 
mammalian expression vector containing the se- 
lectable neomycin phosphotransferase gene. The re- 
suiting recombinant plasmids were transfected into 
the CHO cell line DG44 by electroporation using a 
gene pulser. The selection of the clones as well as 
their main characteristics have already been pub- 
lished [2,3,5,18]. 
Cells were maintained in c~-minimal essential 
medium (oz MEM), supplemented with 10% foetal 
calf serum, 2 mM L-glutamine, 100/xg/ml  penicillin 
and 100 /xg/ml streptomycin with an atmosphere of 
95% air, 5% CO 2 at 37°C. Geneticin (0.5 mg/ml )  
was maintained in the culture medium of the stock 
culture. Subcultures prepared for membrane purifica- 
tion were done in a medium without geneticin. 
2.2. Membrane preparation, receptor identification 
and adenylate cyclase activity determination 
Cells were harvested with a rubber policeman and 
pelleted by low speed centrifugation; the supernatant 
was discarded and the cells lysed in 1 mM NaHCO 3 
and immediate freezing in liquid nitrogen. After 
thawing, the lysate was first centrifuged at 4°C for 10 
rain at 400 × g and the supernatant was further cen- 
trifuged at 20 000 × g for 10 min. The pellet, resus- 
pended in 1 mM NaHCO 3, was used immediately as 
a crude membrane preparation. [~25I]VIP (specific 
radioactivity of 0.7 mCi/mmol) ,  [125I]Ac-HisL 
Table 1 
Amino acid sequence of the peptides testedAll the peptides were carboxy terminally amidated 
1 5 10 15 20 25 
VIP HSDA VFTDN YTRLR KQMAV KKYLN S ILN 
PACAP HSDG IFTDS YSRYR KQMAV KKYLA AVL  
pSn a HSDG TFTSE LSRLR DSARL  QRLLQ GLV 
~bSn a HSDG TLTSE LSRLR DRARL QRLLQ GLL  
[L6]Sn HSDG TLTSE LSRLR DSARL  QRLLQ GLV 
[Rl6]Sn HSDG TFTSE LSRLR DRARL QRLLQ GLV 
a pSn = porcine secretin; rabSn = rabbit secretin = [L6,RJ6,L27]pSn. 
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PACAP-27 (specific radioactivity of 0.5 mCi /mmol)  
and [125I]secretin (specific radioactivity of 0.3 
mCi /mmol  were obtained as described previously 
[2,3,5]. Binding of the tracers to membranes was 
performed as described [2,3,5]. 
In all cases, the non-s, pecific binding was defined 
as the residual binding in the presence of 1 /xM of 
the unlabelled peptide corresponding to the tracer. 
Adenylate cyclase activity was determined by the 
Salomon et al. method ][19] as previously described 
[6]. 
2.3. Peptide synthesis 
All peptides were synthesized as C-terminal amides 
by solid phase methodology on an Automated Ap- 
plied Biosystems apparatus using the Fmoc (9-fluo- 
renylmethoxycarbonyl) strategy as described [6]. 
The peptides were cleaved and purified by reverse 
phase chromatography on DVB 300 A (10 × 1 cm) 
and by ion exchange chromatography on Mono S HR 
5/5.  The peptide purity was assessed (95%) by 
capillary electrophoresis and the sequence conformity 
was verified by direct sequencing and ion spray mass 
spectrometry. 
3. Results 
m 100 
N 50. 
ff 
O, 
(~ ISn RECEPTOR 
~ ~- -~"~"~~ [L 6, R ~5, L 27] Sn 
/ \ \  \ \  
Sn /~ '~o~ [L6, Sn ~ '  
[F06] Sn \~,  "~*"- 
o .  
H >, 
100- 
50- 
~) IVlP I RECEPTOR I 
' ~ / ~ ~ ~ ~  [L 6] Sn 
[L6' R'6' L27'Sn ~ X~.  ~'A 
Sn 
-I0 -9 -B -7 -6 -5 
[PEPTIDE] (log M) 
Fig. 1. Dose-dependent inhibition of [125I]-secretin binding (up- 
per panel) or [125 I]-VIP binding (lower panel) to membranes from 
CHO cells expressing the recombinant rat secretin receptor or the 
rat VIP 1 receptor, respectively, by porcine secretin (Sn, m), 
rabbit secretin ([L 6, R |6, L 27 ] Sn, O), Leu 6 secretin ([L 6 ] Sn, zx), 
or by Arg |6 secretin ([R16]Sn, II). The results were the means of 
3 determinations and were expressed in % of tracer specifically 
bound. 
3.1. Preliminary studies on the potency and selectiv- 
ity of rabbit secretin 
Rabbit secretin or [L 6, R 16, L 27 ] secretin bound to 
the rat secretin receptor with a 6-fold lower affinity 
than secretin. [L 6] secretin was indistinguishable from 
rabbit secretin while []~16] secretin was 2-fold less 
potent han secretin (Fig. 1). 
[L 6, R 16, L 27 ] secretin had a 3-fold higher affinity 
than secretin for the rat VIPj receptor. [L 6] secretin 
had a 3-fold lower affinity and [Arg 16] secretin a 
20-fold higher affinity than secretin for the VIP~ 
receptor. Thus, rabbit secretin was more VIP-like 
than secretin and this preference was due to the 
substitution of Ser by Arg in position 16. 
3.2. Properties of [R m] VIP and [R 16] PACAP 
[R 16 ] VIP and [R 16 ] PACAP-27 had a 4-fold higher 
affinity than VIP and PACAP-27 for the VIP 1 recep- 
tor and a 10- and 4-fold higher affinity for the 
PACAP I receptor (Fig. 2). [R 16] secretin had also a 
greater affinity than porcine secretin for the PACAP 
receptor but the effect of Ser-Arg replacement could 
not be evaluated quantitatively, due to the low affin- 
ity of secretin for that receptor. 
Thus, incorporation of arginine in position 16 of 
secretin, VIP and PACAP-27 increased the peptides 
affinities for VIP 1 and PACAP receptors, respec- 
tively. 
Furthermore (data not shown), [R 16] VIP and [R 16 ] 
PACAP had a lower affinity than VIP and PACAP 
for the secretin receptor. 
The [R 16 ] substituted secretin, VIP and PACAP 
were also tested for their capability to stimulate 
adenylate cyclase activity. The dose-effect curves 
obtained on the three recombinant receptors con- 
firmed the binding data: in cell membranes express- 
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Fig. 2. Dose-dependent i hibition of [usI]-VIP binding (upper 
panel) or [125I]-Ac-HisLPACAP-27 binding (lower panel) to 
membranes from CHO cells expressing the recombinant rat VIP~ 
receptor or the rat PACAP I receptor, respectively, by VIP (O), 
PACAP (zx), secretin (r q) and the Arg 16 substituted peptides, 
[R 16] VIP (Q), [R 16] PACAP (A) and [R 16] secretin (11). The 
results were the means of 3 determinations and were expressed in
% of tracer specifically bound. 
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Fig. 3. Dose-effect curves of VIP (O), [R 16] VIP (O), PACAP 
(A), [R 16] PACAP (A), secretin ([3) and [RI6]secretin ( l l )  on 
adenylate cyclase activation in membranes from CHO cells ex- 
pressing the recombinant rat secretin receptor. The results ex- 
pressed in pmol cyclic AMP produced/rain, mg protein were the 
means of three experiments. 
pared in this work the potencies of [R 16] substituted 
peptides and of the native peptides for cyclase activa- 
tion through these chimeric receptors. 
[R 16] secretin, [R 16] VIP and [R 16] PACAP had 
lower potencies than the unsubstituted peptides on 
ing the secretin receptor (Fig. 3), [R 16] secretin, [R 16] 
VIP and [R 16] PACAP were 2.5-, 6.0- and 3.0-fold 
less potent han the corresponding unsubstituted pep- 
tides; in cell membranes expressing the VIP~ receptor 
(Fig. 4), [R 16] secretin, [R 16] VIP and [R 16] PACAP 
were 10-, 3- and 2-fold more potent han the unsub- 
stituted peptides; and in cell membranes expressing 
the PACAP receptor, [W °] secretin, [R 16] VIP and 
[R t6] PACAP were respectively 8-, 4- and 2-fold 
more potent han the unsubstituted peptides (Fig. 5). 
We have previously cloned CHO cells expressing 
chimeric receptors consisting in the N-terminal part 
of the secretin receptor grafted on the core of the 
VIP t receptor (N-Sn/VIP 0 or the N-terminal part of 
the VIPt receptor grafted on the core of the secretin 
receptor (N-VIP l/Sn.r). As previously published [18], 
tracer binding studies were not possible on these 
membranes, but functional data could be obtained by 
adenylate cyclase activity determination. We corn- 
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Fig. 4. Same experimental design, symbols and expression of the 
results as in Fig. 3 but the study was performed on membranes 
from CHO cells expressing the recombinant rat VIPj receptor. 
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results as in Figs. 3 and 4 but the study was conducted on CHO 
cell membranes expressing the recombinant rat PACAP I recep- 
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Fig. 6. Dose-effect curves of secretin [] and [R 16] secretin ( l l )  
on adenylate cyclase activation in membranes from CHO cells 
expressing the recombinant chimeric N-Sn/VIP I (upper panel) or 
N-VIPj/Sn (lower panel) receptor. Same expression of the re- 
sults as in Figs. 3-5. 
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Fig. 7. Dose-effect curves of VIP (O), [RJ6]VIP (O), PACAP 
(A)  and [RJ6]PACAP (A)  on adenylate cyclase activation in 
membranes from CHO cells expressing the recombinant chimeric 
N-Sn/VIP 1 (upper panel) or N-VIP 1/Sn (lower panel) receptor. 
Same expression of the results as in Figs. 3-6. 
N-Sn/VIP~ receptors and higher potencies on N- 
V IP JSn receptors (Figs. 6 and 7). Thus a similar 
selectivity profile was found for the secretin receptor 
and the N-Sn/VIP~ receptor on one hand and for the 
VIP l and N-VIPI/Sn receptors on the other hand. 
4. Discussion 
We first observed in the present study that rabbit 
secretin was less potent than porcine secretin on rat 
secretin receptors but more potent on VIP~ receptors. 
Rabbit secretin differs from porcine secretin in posi- 
tions 6, 16 and 27 [14]. Substitution of the C-terminal 
Va127-NH2 by Leu27-NH2 was not investigated di- 
rectly as it was considered of limited consequence: 
indeed, both amino acids were hydrophobic and the 
C-terminal 20-27 part of secretin can be replaced by 
the 20-27 sequence of PACAP without any modifi- 
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cation of peptide potency (unpublished results). Intro- 
duction of a Leu- instead of a Phe residue in position 
6 of secretin decreased markedly the peptide potency 
on both rat secretin and VIP 1 receptors. Phe 6, that is 
conserved in all members of the VIP/Sn/glucagon 
family of peptides, is usually considered as essential 
for biological activity: [Tyr 6] secretin displayed 1% 
of the secretin activity [20], [D-Phe 6] secretin was 
inactive in in vivo models [21] and 300-fold less 
active than secretin in rat cardiac membranes [22], 
[hexahydro-Phe 6] secretin had also a reduced activity 
both in vivo and in vitro [21]. 
Introduction of Arg16 instead of Ser in secretin or 
Gin in VIP and PACAP decreased the peptides affini- 
ties for the secretin receptor but increased their affini- 
ties for the VIP~ and PACAP receptors. These results 
were rather unexpected as position 16 has never been 
considered as important for secretin, VIP~ or PACAP 
receptor recognition. In both VIP and PACAP 
molecules, it is assumed that, followed a /3-turn 
involving residues 7 to 10, the peptides adopt a 
continuous a-helix conformation [12,23,24] or two 
helical structures eparated by an unidentified struc- 
ture between amino acids 14 to 21 [12,25]. In secretin 
however, Ser ~6 is thought to be involved in the 
13-16 reverse turn connecting the two a-helix struc- 
tures 7 to 11 and 17 to 24 [25]. It is possible that the 
introduction of a charged amino acid in position 16 
disturbs the peptides tructures. 
The increased affinity of the three Arg ~6 peptides 
for the VIP 1 and PACAP receptors could result either 
from the introduction of a new bond between the 
receptor and the ligand or from stabilization of a 
ligand conformation that fits better in the binding 
pocket of the receptor. 
Whatever the explanation, it appears that Arg 16 
interacts with the N-terminal domain of the secretin 
and the VIP 1 receptors: indeed, the chimeric recep- 
tors having only the N-terminal domain of secretin or 
VIP behave like the entire secretin and VIP l recep- 
tors, respectively. 
This N-terminal domain of both receptors was 
already found to be responsible for the discrimination 
between secretin and VIP [18,26] whereas the first 
extracellular loop of the receptor interacted with the 
N-terminal part of the ligand [27]. Due to their poten- 
tial application in human therapy, and particularly in 
asthma, VIP analogues with a high stability and 
affinity have been developed: the combination of a 
C-terminal extension that stabilizes the terminal a- 
helix, of N-acetylation and of cyclisation between 
positions 21 to 25 led to the RO 25-1553 compound 
that was 10-fold more potent than VIP for tracheal 
smooth muscle relaxation [28]. We would like to 
suggest hat introduction of an Arg 16 residue might 
result in a further increase in peptide bioactivity if it 
acts through interaction with the VIP 1 receptor. It 
remains indeed to establish if the Arg 16 derivatives 
have also an increased potency on the VIP 2 receptor 
[29-31] distinct pharmacologically from the VIPI 
receptor by its extremely low affinity for secretin. 
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